Determining the Evidence Requirements to Optimize Market Access for Two Oncology Therapies Launching in Key European Markets

A large biotech company was preparing to launch two new oncology therapies in five key European markets. It needed to determine what evidence packages would optimize pricing and market access in those markets. It also needed to understand the market access impact of various launch scenarios to identify the optimum one.

The project involved four key phases. The first phase involved assessing the current and future market landscape for the therapies in question. With that information in hand, the team moved on to phase two: hypothesizing the various evidence scenarios that would need to be analyzed, as well as their potential implications. In phase three, the Blue Matter team interviewed EU payers to pressure-test their hypotheses and gather additional insights. In the final phase, our team synthesized the insights gathered from the research and issued final recommendations to the client.

The client was able to determine the evidence packages that would be most relevant to payers in their priority markets, as well as identify the optimum launch scenario for the two therapies. Blue Matter was retained to continue supporting the client’s launch efforts.